Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-03-07 12:29 pm Sale |
2024-02-29 | 13G | Merrimack Pharmaceuticals, Inc. MACK |
BLACKROCK INC BLK |
715,279 4.990% |
-28,344 (-3.81%) |
Filing History |
| 2024-02-22 4:46 pm Purchase |
2024-02-13 | 13G | Merrimack Pharmaceuticals, Inc. MACK |
ADAR1 Partners LP | 902,350 6.300% |
902,350 (New Position) |
Filing History |
| 2024-02-14 4:20 pm Sale |
2023-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK |
22NW Fund LP | 0 0.000% |
-1,015,048 (Position Closed) |
Filing History |
| 2024-01-31 2:08 pm Purchase |
2023-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK |
BLACKROCK INC BLK |
743,623 5.200% |
422,576 (+131.62%) |
Filing History |
| 2024-01-25 4:05 pm Purchase |
2023-01-17 | 13D | Merrimack Pharmaceuticals, Inc. MACK |
Newtyn Management, LLC | 1,873,694 13.100% |
354,587 (+23.34%) |
Filing History |
| 2023-12-13 4:05 pm Purchase |
2023-12-07 | 13D | Merrimack Pharmaceuticals, Inc. MACK |
Western Standard, LLC | 2,220,058 15.500% |
228,950 (+11.50%) |
Filing History |
| 2023-08-14 4:05 pm Purchase |
2022-12-29 | 13D | Merrimack Pharmaceuticals, Inc. MACK |
Western Standard, LLC | 1,991,108 13.900% |
802,263 (+67.48%) |
Filing History |
| 2023-02-14 4:04 pm Sale |
2022-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK |
Point72 Asset Management, L.P. | 0 0.000% |
-900,981 (Position Closed) |
Filing History |
| 2023-02-13 4:20 pm Purchase |
2022-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK |
22NW Fund LP | 1,015,048 7.600% |
1,015,048 (New Position) |
Filing History |
| 2022-08-04 4:28 pm Purchase |
2022-08-03 | 13G | Merrimack Pharmaceuticals, Inc. MACK |
Point72 Asset Management, L.P. | 900,981 6.700% |
900,981 (New Position) |
Filing History |
| 2022-02-14 12:50 pm Unchanged |
2021-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK |
22NW LP | 1,241,896 9.300% |
0 (Unchanged) |
Filing History |
| 2022-02-14 08:19 am Sale |
2021-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK |
Nantahala Capital Management, LLC | 569,971 4.300% |
-181,872 (-24.19%) |
Filing History |
| 2021-02-12 5:13 pm Sale |
2021-02-16 | 13G | Merrimack Pharmaceuticals, Inc. MACK |
DIMENSIONAL FUND ADVISORS INC | 550,539 4.100% |
-122,591 (-18.21%) |
Filing History |
| 2021-02-12 4:01 pm Purchase |
2020-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK |
22NW LP | 1,241,896 9.280% |
289,533 (+30.40%) |
Filing History |
| 2021-02-12 06:46 am Purchase |
2020-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK |
Nantahala Capital Management, LLC | 751,843 5.600% |
4,208 (+0.56%) |
Filing History |
| 2020-12-02 7:21 pm Purchase |
2020-11-24 | 13D | Merrimack Pharmaceuticals, Inc. MACK |
Western Standard, LLC | 1,188,845 8.900% |
142,217 (+13.59%) |
Filing History |
| 2020-12-02 2:18 pm Purchase |
2020-11-24 | 13D | Merrimack Pharmaceuticals, Inc. MACK |
Newtyn Management, LLC | 1,519,107 11.400% |
142,227 (+10.33%) |
Filing History |
| 2020-07-24 5:42 pm Purchase |
2020-07-22 | 13D | Merrimack Pharmaceuticals, Inc. MACK |
Newtyn Management, LLC | 1,376,880 10.300% |
203,714 (+17.36%) |
Filing History |
| 2020-07-23 8:44 pm Purchase |
2020-07-22 | 13D | Merrimack Pharmaceuticals, Inc. MACK |
Western Standard, LLC | 1,046,628 7.800% |
203,715 (+24.17%) |
Filing History |